Tasly Pharmaceutical Group Co Ltd (600535) — Cash Flow-to-Debt Ratio
Tasly Pharmaceutical Group Co Ltd (600535) has a Cash Flow-to-Debt Ratio of 0.20x as of December 2025, meaning its operating cash flow of CN¥552.13 Million could theoretically repay 0% of its total liabilities (CN¥2.79 Billion) in one year. See 600535 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Tasly Pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio (2001–2025)
Historical debt coverage capacity for Tasly Pharmaceutical Group Co Ltd across 25 annual periods. Also explore 600535 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Tasly Pharmaceutical Group Co Ltd (2001–2025)
Year-by-year debt coverage analysis for Tasly Pharmaceutical Group Co Ltd. For market capitalisation and broader financial context, see 600535 stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.51x | CN¥1.42 Billion | CN¥2.79 Billion | ▼ -27.4% |
| 2024 | 0.70x | CN¥2.01 Billion | CN¥2.87 Billion | ▲ +9.9% |
| 2023 | 0.64x | CN¥2.58 Billion | CN¥4.02 Billion | ▲ +6.4% |
| 2022 | 0.60x | CN¥2.29 Billion | CN¥3.80 Billion | ▼ -30.7% |
| 2021 | 0.87x | CN¥2.80 Billion | CN¥3.23 Billion | ▲ +99.1% |
| 2020 | 0.44x | CN¥1.79 Billion | CN¥4.11 Billion | ▲ +215.2% |
| 2019 | 0.14x | CN¥1.68 Billion | CN¥12.15 Billion | ▲ +29.3% |
| 2018 | 0.11x | CN¥1.49 Billion | CN¥13.96 Billion | ▲ +263.3% |
| 2017 | -0.07x | CN¥-822.56 Million | CN¥12.56 Billion | ▼ -150.6% |
| 2016 | 0.13x | CN¥1.15 Billion | CN¥8.92 Billion | ▲ +193.2% |
| 2015 | 0.04x | CN¥340.00 Million | CN¥7.71 Billion | ▼ -43.8% |
| 2014 | 0.08x | CN¥616.76 Million | CN¥7.85 Billion | ▲ +37.7% |
| 2013 | 0.06x | CN¥346.17 Million | CN¥6.07 Billion | ▼ -54.7% |
| 2012 | 0.13x | CN¥413.31 Million | CN¥3.28 Billion | ▲ +166.6% |
| 2011 | 0.05x | CN¥135.14 Million | CN¥2.86 Billion | ▼ -75.7% |
| 2010 | 0.19x | CN¥395.05 Million | CN¥2.03 Billion | ▼ -9.8% |
| 2009 | 0.22x | CN¥400.39 Million | CN¥1.85 Billion | ▲ +12.5% |
| 2008 | 0.19x | CN¥260.21 Million | CN¥1.36 Billion | ▼ -3.0% |
| 2007 | 0.20x | CN¥221.55 Million | CN¥1.12 Billion | ▲ +116.8% |
| 2006 | 0.09x | CN¥140.56 Million | CN¥1.54 Billion | ▼ -49.5% |
| 2005 | 0.18x | CN¥214.90 Million | CN¥1.19 Billion | ▼ -26.5% |
| 2004 | 0.25x | CN¥203.27 Million | CN¥826.42 Million | ▲ +140.0% |
| 2003 | 0.10x | CN¥59.00 Million | CN¥575.74 Million | ▼ -87.4% |
| 2002 | 0.81x | CN¥206.22 Million | CN¥253.70 Million | ▲ +237.9% |
| 2001 | 0.24x | CN¥83.77 Million | CN¥348.19 Million | — |